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Abstract
Background: Tat is being tested as a component of HIV vaccines. Tat activity has been mainly
investigated on cells of lymphoid/hematopoietic lineages. HIV-1, however, is known to infect many
different cells of both solid organs and mucosal surfaces. The activity of two-exon (aa 1–101) and
synthetic (aa 1–86) Tat was studied on mammary and amniotic epithelial cells cultured under low
serum conditions.
Results: small concentrations of Tat (100 ng/ml) stimulated cell proliferation. Tat antibodies
neutralized the mitogenic Tat activity. Changes of gene expression in Tat-treated cells were
evaluated by RT-PCR and gene-array methods. Within 4 hours of treatment, exposure to Tat is
followed by up-regulation of some cell cycle-associated genes (transcription factors, cyclin/cdk
complexes, genes of apoptotic pathways) and of genes relevant to HIV pathogenesis [chemokine
receptors (CXCR4, CCR3), chemotactic cytokines (SDF-1, RANTES, SCYC1, SCYE1), IL6 family
cytokines, inflammatory cytokines, factors of the TGF-beta family (TGFb, BMP-1, BMP-2)]. Up-
regulation of anti-inflammatory cytokines (IL-10, IL-19, IL-20), a hallmark of other persistent viral
infections, was a remarkable feature of Tat-treated epithelial cell lines.
Conclusion:  extracellular Tat is mitogenic for mammary and amniotic epithelial cells and
stimulates the expression of genes of pathogenetic interest in HIV infection. These effects may
favor virus replication and may facilitate the mother-to-child transmission of virus.
Background
Numerous extracellular roles for the HIV-1 transactivator
protein (Tat) have emerged from experiments showing
that Tat is taken up by cultured cells, enters the nucleus,
and transactivates genes linked to the HIV LTR [1].
Early experiments showing that recombinant Tat was able
to inhibit antigen-induced, but not mitogen-induced,
proliferation of peripheral blood mononuclear cells indi-
cated Tat as a viral immunosuppressant [2]. This view has
been confirmed by subsequent observations indicating
that: a) Tat down-regulates HLA class I [3] and class II [4]
expression in T-lymphocytes and macrophages, b) Tat
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represses transcription of the mannose receptor [5] a key
molecule in the early response to invading pathogens, c)
Tat suppresses CD26-dependent T cell proliferation [6], d)
Tat down-regulates TCR/CD3 surface complexes [7], e)
Tat induces suppressive levels of alpha interferon in T cells
[8], and f) Tat causes human monocytes to secrete inter-
leukin-10 (IL-10) an anti-inflammatory cytokine [9].
Extracellular Tat may stimulate virus replication and dis-
ease either through receptor-mediated signal transduction
or after internalization and transport to the nucleus [10].
The basic domain of Tat protein (aa 45–56) is required for
the binding to the viral transactivation-responsive ele-
ment (TAR) and for importingextracellular Tat into the
cell [11]. Low concentrations of extracellular Tat – similar
to those measured in HIV-infected humans, i.e. 2–40 ng/
ml [12] – have been shown to promote angiogenesis [13],
to stimulate growth and motility of cultured Kaposi sar-
coma cells [14], to induce monocyte chemotaxis through
the synthesis of platelet-activating factor [15], to stimulate
vascular permeability and the recruitment of mononu-
clear cells [16]. Thus, Tat has been shown to act through
several pathways to establish an adequate cellular envi-
ronment enhancing viral replication.
The multiple pathogenetic activities of extracellular Tat in
HIV-infected individuals are unclear, but vaccination with
native Tat or detoxified derivatives is being tested to pre-
vent pathogenic events that would otherwise lead to a
spreading infection [17,18]. The rationale for this
approach is that Tat is conserved among different virus
strains [19] and that vaccination might also protect unin-
fected bystander cells. Human antibodies to Tat correlate
with nonprogression of HIV disease [20,21] and have
been shown to reduce virus production in HIV-infected
cell lines [22]. Remarkably, monkeys immunized with Tat
and other HIV antigens were protected from challenge
with simian/human immunodeficiency virus [18,23].
For using biologically active Tat as an immunogen, it is
desirable to better define its activity on a wide variety of
human cells. In this context, it should be considered that
most studies have been carried out on cultured cells of
lymphoid origin [5,24], whereas HIV-1 is capable of
infecting numerous types non-lymphoid cells derived
from solid tissues [reviewed in [25]]. As an example, HIV
has been shown to affect the viability and functions of
lung fibroblasts [26], vascular endothelial cells [27], kid-
ney glomerular mesangial cells [28], as well as epithelial
cells derived from the mammary gland [29], intestine
[30], and kidney [31].
Our laboratory has shown that primary cultures of mam-
mary epithelial cells (MEC) – that are possibly implicated
to the mother-to-child transmission of infection – do
express surface CD4, galactosylceramide and CD26 and
can be infected by HIV-1 [29]. Infection was associated
with the up-regulation of surface HLA class-II molecules
and CD26, while the expression of CD4, tissue-specific
markers, adhesion molecules and growth factor receptors
was downregulated by the virus. Cytopathic effect ensued.
Hormones (T3, alpha-estradiol and prolactin) enhanced
HIV replication, possibly by stimulating cell proliferation.
Here we analyzed the effects of exogenous Tat protein on
epithelial cells of mammary and amniotic origin. It was
found that the HIV-1 transactivator induces the above
cells to proliferate and that – a few hours after treatment –
expression of surface receptors, cytokines and growth fac-
tors of pathogenetic relevance in HIV infection is up-regu-
lated.
Results
Cell proliferation in response to exogenous Tat
Preliminary experiments with a variety of epithelial cell
lines have shown that only marginal proliferative
responses to Tat were observed when cells were grown in
complete medium (i.e., medium containing 10% FBS). In
contrast, experiments performed using LSM revealed a
marked proliferative effect of Tat on epithelial cells. The
activity of various doses of Tat was evaluated with two
methods: 1) the XTT assay and 2) cell counts. As shown in
Figure 1, the XTT assay showed significant proliferative
responses when MCF-7 and MEC-1 cell lines were
exposed for 2 days to doses of Tat ≥  50 ng/ml. Equivalent
results have been obtained with recombinant Tat101aa and
synthetic Tat86aa protein preparations (as detailed in the
Materials and Methods section). Thus, in subsequent
experiments cell cultures were exposed to 100 ng/ml of
Tat for different periods of time. In addition to the XTT
method, cell proliferation has been measured by direct
microscopic counts of cell monolayers. An example of the
results is given in Figure 2. Different numbers of adherent
cells can be observed in cultures of MCF-7 and MEC-1
cells either untreated or treated with Tat 100 ng/ml for 36
h. Comparable results have been obtained with several
different epithelial cell lines. As shown in Figure 3, Tat
consistently induced the proliferation of four different
lines of mammary epithelial cells and of the amniotic AV-
3 cell line. In these experiments it was also shown that a
monoclonal anti-Tat antibody was capable of neutralizing
Tat proliferative activity. Using the AV-3 cell line, the Tat-
neutralizing activity of a rabbit polyclonal antibody was
also demonstrated (bottom panel). Unrelated mono-
clonal and polyclonal antibodies to coxsackievirus B4
failed to neutralize Tat activity (data not shown). The hor-
mone-dependent spontaneously immortalized MCF-10A
line gave the lowest response to Tat, whereas consistently
higher responses were observed with MCF-7 mammary
cells and AV-3 amniotic cells. Thus, these two cell linesBMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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have been investigated in more detail to study the influ-
ence of exogenous Tat on gene expression profile.
RT-PCR analysis: Tat modulation of HIV-1 receptors, 
growth factors, and cytokine transcripts
Semiquantitative RT-PCR was used to evaluate transcript
expression in cell cultures exposed to Tat. Primers for
cytokines and VEGF were used in conjunction with a
series of published primers (Table 1) to detect alterations
of receptor, growth factor and cytokine transcript expres-
sion. Different time points were used (i.e., 1, 3, 6 and 12
h post-treatment). As shown by transcript analysis of
selected HIV-1 receptors/co-receptors, gene up-regulation
was observed early after Tat treatment (i.e., 3–6 h). Results
relative to the MCF-7 and MEC-1 cell lines are reported in
Table 2. Comparable results have been obtained with
other mammary cell lines (data not shown). CD4 is
expressed at low-levels in all investigated cell lines. Tat
failed to influence CD4 expression. CXCR4, CCR3, and
CCR4 transcripts were consistently up-regulated after 3–6
h treatment with Tat. In contrast, CCR1, CCR2, and CCR5
transcripts were not expressed. As shown in Figure 4, up-
regulation of VEFG (mainly the 165 isoform) was
observed in MCF-7 cells early after Tat exposure (1–3 h).
This was concomitant with the up-regulation of VEGF
receptor-2 (Flk-1/KDR). This result indicates the possibil-
ity of an autocrine loop contributing to Tat-stimulated cell
proliferation. VEGF up-regulation was also observed in
the other epithelial cell lines using the gene-array tech-
nique. Up-regulation of IL-6 and IL-6 receptor has also
been detected in MCF-7 and AV-3 cells (data not shown).
IL-6 has been shown to contribute to epithelial cell differ-
entiation in both thyroid and the mammary gland [32].
Tat did not influence the expression of IL-8, a neutrophil-
attracting cytokine produced by mammary epithelial cells
[32]. Exposure to Tat for 4 h was followed by up-regula-
tion of TGF-beta1 and TGF-beta2 in MCF-7 and AV-3
cells. Real time RT-PCR confirmed that the expression of
IL-6, IL-6-R, TGF-beta1, and VEGF (isoform 165) was
enhanced from 2.4- to 6.5-fold in cells treated with Tat for
4 h. As seen by RT-PCR, expression of CPSF3 [33] was not
modified by 1 to 12 h treatment with Tat (data not
shown).
Growth of mammary epithelial cells exposed to different  doses of Tat101aa Figure 1
Growth of mammary epithelial cells exposed to dif-
ferent doses of Tat101aa. Cells were cultured in low-serum 
medium. Growth was measured by the XTT assay after 48 h 
of Tat treatment. Each bar represents the average of 3 differ-
ent tests + SD. *, P < 0.05, as compared with untreated cell 
cultures.
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Monolayers of MCF-7 and MEC-1 cells cultured in low-serum  medium and treated or not with extracellular Tat101aa (100  ng/ml for 36 hours) Figure 2
Monolayers of MCF-7 and MEC-1 cells cultured in 
low-serum medium and treated or not with extracel-
lular Tat101aa (100 ng/ml for 36 hours). Increased num-
bers of cells can be observed in Tat-treated cultures as 
compared to untreated control cultures. Phase contrast; 
microscopic fields taken with a 10× objective.
Untreated Tat 100 ng/ml
MCF-7
MEC-1BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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Gene array studies. Genes up-regulated by Tat in both 
MCF-7 and AV-3 cell lines
Gene-arrays were used to compare gene expression in con-
trol untreated and Tat-treated cell cultures. Tables 3 and 4
summarize the results of cultures of MCF-7 and AV-3 cells
exposed to Tat for 4 h. Genes that were up-regulated ≥ 1.5-
fold in both cell lines are reported. Up-regulation is
expressed as change (n-fold) for each cell line. The last col-
umn shows the average up-regulation in the two cell lines.
Fifty of 96 genes (52%) related to the cell cycle were up-
regulated from 1.7- to 4.6-fold. Twenty-four of 167 genes
(14.4%) coding for growth factors, cytokines and their
receptors were up-regulated from 1.6- to 3.7-fold.
The up-regulation of a wide spectrum of genes involved in
cell cycle regulation that is presented here for two epithe-
lial cell lines confirms the observed proliferative effect of
Tat on non-lymphoid cell lines. As shown in Table 3, Tat
treatment was associated with increased expression of: a)
transcription factors (E2F, E2F-6, MPP2); b) cyclins (cyc-
lin E1, E2, F, B, B2, C, D1, G, H); c) cyclin-dependent
kinases and associated proteins (cdk6, cdk7, cdk8, protein
regulating cytokinesis-1, cks1p9, cks2); d) cell division
cycle proteins cdc27, cdc34, cdc37, cdc45); e) genes
involved in DNA repair (MRE11A, nibrin, Hus1, RAD17,
RAD50); f) cullins and associated proteins (cul-1, RBX1,
Neutralization by anti-Tat antibodies of the proliferative  response to Tat of five different human epithelial cell lines  cultured in low-serum medium Figure 3
Neutralization by anti-Tat antibodies of the prolifer-
ative response to Tat of five different human epithe-
lial cell lines cultured in low-serum medium. Cells 
were either left untreated (open bars) or exposed to 100 ng/
ml Tat86aa (closed bars) at time 0. Cells were counted by 
microscopy at day-0, -1 and -2 after plating. Antibody tMAb-
B (1 µg/ml) was mixed with Tat before treatment (red bars) 
or given alone (green bars). Bars represent the mean of three 
wells. Experiments on AV-3 cells (bottom panel) have also 
demonstrated the Tat-neutralizing activity of a rabbit poly-
clonal anti-Tat antibody: anti-Tat plus Tat (yellow bars) and 
anti-Tat alone (gray bars). Results are expressed as number 
of cells/well. Each bar represents the average of 3 different 
tests. Standard deviations of the mean are not reported, but 
were within 12% of the mean.
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Semiquantitative RT-PCR of VEGF family genes in MCF-7  cells cultured in low-serum medium and exposed for differ- ent times to extracellular Tat86aa Figure 4
Semiquantitative RT-PCR of VEGF family genes in 
MCF-7 cells cultured in low-serum medium and 
exposed for different times to extracellular Tat86aa. 
Increased expression of the VEGF receptor-2 (Flk-1/KDR) 
and VEGF isoform 165. To a lower extent, the VEGF iso-
form-121 was also up-regulated. The GAPDH signal was 
used as a control. MW, DNA molecular weight ladder.
MW Tat 100ng/ml
0h 1h 3h 6h 12h
Flk-1/KDR
GAPDH
VEGF-189
VEGF-165
VEGF-121BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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Skp1, Skp2, Cul-2, Cul-3, Cul-4A, Cul-4B); g) nuclear fac-
tors associated with DNA replication (Ki67, PCNA, rpa,
MCM2, MCM4, MCM5, MCM7); h) factors involved in
cell cycle arrest (c-abl, chk1, cyclin G2, p18,, P21Cip1,
p27Kip1); i) apoptosis-related genes (mdm2, bax).
Tat treatment was also associated with the increased tran-
scription of selected growth factors, cytokines and recep-
tors. Table 4 shows that the following genes were up-
regulated in both MCF-7 and AV-3 cells: a) cytokines of
the IL-6 superfamily and a signal-transducing molecule
Table 1: Primers used to evaluate the expression of mRNA transcripts by RT-PCR.
Gene GenBank Accession No. Primer 5'-3' sequence
beta-actin NM001101 Fwd ATCTGGCACCACACCTTCTACAATGAGCTGCG
Rvs CGTCATACTCCTGCTTGCTGATCCACATCTGC
CD4 BC025782 Fwd GTGAACCTGGTGGTGATGAGAGC
Rvs GGGGCTACATGTCTTCTGAAACCGGTG
CXCR-4 BC020968 Fwd CTGAGAAGCATGACGGACAAGTACAG
Rvs CAACAGCTTCCTTGGCCTCTGACT
CCR-1 NM001295 Fwd GGAAACTCCAAACACCACAGAGGA
Rvs AAGATCTCGCTGTACAAGCCTGTG
CCR-2 NM000647 Fwd CTCTCCCATTGTGGGCTCACTCTG
Rvs GCAAACACAGCATGGACAATAGCC
CCR-3 AF026535 Fwd CTATGATGACGTGGGCCTGCTC
Rvs AAGATCTCGCTGTACAAGCCTGTG
CCR-4 NM005508 Fwd CACCAAAGAAGGCATCAAGGCAT
Rvs TGCCACTGTAAAAGCCCACCAAG
CCR-5 NM000579 Fwd CCTGATAAACTGCAAAAGGCTGAAG
Rvs AGCAAACACAGCATGGACGACAG
IL-6 NM000600 Fwd ATGAACTCCTTCTCCACAAGCGC
Rvs GAAGAGCCCTCAGGCTGGACTG
IL-6R X12830 Fwd CATTGCCATTGTTCTGAGGTTC
Rvs AGTAGTCTGTATTGCTGATGTC
IL-8 NM000584 Fwd ATGACTTCCAAGCTGGCCGTGGCT
Rvs TCTCAGCCCTCTTCAAAAACTTCTC
TGF-beta 1 NM000660 Fwd GCCCTGGACACCAACTATTGCT
Rvs GGACGGGGATGTAAACCTCGGA
TGF-beta 2 M19154 Fwd GATTTCCATCTACAAGACCACGAGGGACTTGC
Rvs GCTTACCGAGAGGAAGCTACATTGACTACGAC
CPFS3 AF171877 Fwd AATGGCTGGCAAACCCTTCTAATG
Rvs CATCGTCTTCACTTCCCTCTTCACA
Table 2: Expression of HIV receptors and co-receptors in mammary cells exposed to exogenous Tat protein (100 ng/ml)1.
Cell line CD4 CXCR4 CCR1 CCR2 CCR3 CCR4 CCR5
MCF-7 (untreated) + + - - -/+ -/+ -
MCF-7 + Tat
1  h + + + - - ++-
3 h + ++ - - ++ ++ -
6 h + ++ - - ++ ++ -
MEC-1 (untreated) + + - - -/+ -/+ -
MEC-1 + Tat
1  h + + + - - ++-
3 h + ++ - - ++ ++ -
6 h + ++ - - ++ + -
1. Expression of mRNA transcripts has been evaluated by semi-quantitative RT-PCR as reported in the Materials and Methods section. Transcript 
expression is reported as negative (-) or positive. Band intensity is indicated with 1+, 2+, or 3+.BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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Table 3: Expression profile of cell cycle-related genes in epithelial cell lines exposed for 4 h to exogenous Tat protein (100 ng/ml).
Gene name GenBank 
accession No.
Description Fold change in expression1
MCF-7 cell line 
mean ± SD
AV-3 cell line 
mean ± SD
Mean of the 
two cell lines
P21Waf1 
(p21Cip1)
L47233 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.2 ± .8 5.0 ± .8 4.6
Cdk7 NM 001799 Cyclin-dependent kinase 7 3.8 ± .9 5.2 ± .7 4.5
Cul1 NM 003592 Cullin 1 2.7 ± .6 5.3 ± 1.1 4.0
Cullin-Cul3 NM 003590 Cullin 3 2.6 ± .7 5.3 ± 1.3 3.9
CDC37 U63131 Cell division cycle 37 (S. cerevisiae) homolog 1.9 ± .3 5.9 ± .9 3.9
cyclinD1 M64349 Cyclin D1 (PRAD1 parathyroid adenomatosis 1) 1.8 ± .3 5.8 ± .7 3.8
Cks1p9 NM 001826 CDC28 protein kinase 1 2.4 ± .5 4.9 ± 1.2 3.7
Cullin-Cul4A AF077188 Cullin 4A 2.2 ± .4 4.8 ± 1.1 3.5
Cks2 NM 001827 CDC28 protein kinase 2 1.6 ± .5 5.2 ± 1.1 3.4
CDC45-like1 NM 003504 Cell division cycle 45-like (S. cerevisiae) 5.1 ± 1.4 1.6 ± .4 3.4
CyclinH U11791 Cyclin H 4.0 ± .6 2.6 ± 1.0 3.3
p27Kip1 U10906 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 1.8 ± .2 4.8 ± 1.0 3.3
Cdk8 X85753 Cyclin-dependent kinase 8 1.6 ± .3 4.8 ± .6 3.2
CDC34 L22005 Ubiquitin-conjugating enzyme, cell division cycle 34 3.0 ± .5 3.3 ± .6 3.1
Chk1 AF016582 CHK1 (checkpoint, S. pombe) homolog 1.6 ± .3 4.7 ± .9 3.1
Cyclin G X77794 Cyclin G1 3.2 ± .5 3.0 ± .3 3.1
CyclinG2 L49506 Cyclin G2 2.7 ± .6 3.3 ± .5 3.0
Cdc27 NM 001256 Cell division cycle 27 2.7 ± .8 3.2 ± .7 3.0
p18 U17074 p18 (cdk4 inhibitor) cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4)
2.3 ± .5 3.6 ± 1.0 3.0
E2F U47677 Transcription factor 1 3.8 ± .9 1.9 ± .6 2.9
RAD17 NM 002873 RAD17 (S. pombe) homolog 2.3 ± 1.0 3.3 ± .8 2.8
RAD50 U63139 RAD50 (S. cerevisiae) homolog 2.4 ± .4 3.1 ± .8 2.8
Cullin-Cul2 U83410 Cullin 2 1.5 ± .5 3.8 ± .8 2.7
E2F-6 AF059292 E2F transcription factor 6 2.9 ± .6 2.3 ± .8 2.6
cyclinB2 NM 004701 Cyclin B2 1.8 ± .8 3.2 ± .5 2.5
CyclinF U17105 Cyclin F 3.5 ± .8 1.5 ± .6 2.5
PRC1 NM 003981 Protein regulator of cytokinesis1 2.0 ± .4 3.0 ± .5 2.5
Cullin-Cul4B AB014595 Cullin 4B 2.0 ± .3 2.9 ± .3 2.5
cyclinE1 M73812 Cyclin E1 2.0 ± .4 2.9 ± .3 2.5
Hus1 NM 004507 HUS1 (S. pombe) checkpoint homolog 1.8 ± .8 3.1 ± .2 2.5
MPP2 U74613 Human putative M phase phosphoprotein 2 (MPP2) 
mRNA
1.8 ± .6 3.1 ± .6 2.5
Ki67 (MKI67) X65550 Antigen identified by monoclonal Ab Ki-67 1.5 ± .3 3.3 ± .4 2.4
Skp1 U33760 Cyclin A / CDK2-associated p19 (Skp1) 1.5 ± .3 3.2 ± .6 2.4
Skp2 U33761 Human cyclin A / CDK2-associated p45 (Skp2) 2.0 ± .3 2.7 ± .6 2.4
PCNA J04718 Proliferating cell nuclear antigen 1.9 ± .5 2.8 ± .5 2.4
Bax L22474 Bcl2-associated X protein 1.6 ± .5 3.0 ± .7 2.3
cyclinE2 NM 004702 Cyclin E2 1.5 ± .4 3.1 ± .3 2.3
CyclinB M25753 Cyclin B1 1.7 ± .3 3.1 ± .5 2.4
CyclinC M74091 G1/S-specific Cyclin C 1.6 ± .4 3.0 ± .6 2.3
MCM5 
(CDC46)
NM 006739 Minichromosome maintenance deficient (S. cerevisiae) 5 
(cell division cycle 46)
1.8 ± .2 2.7 ± .4 2.3
MRE11A U37359 Meiotic recombination (S. cerevisiae) 11 homolog A 1.5 ± .7 2.9 ± .5 2.2
Cdk6 X66365 Cyclin-dependent kinase 6 2.0 ± .3 2.3 ± .9 2.2
Nibrin AF058696 Nijmegen breakage syndrome 1 (nibrin) 1.8 ± .4 2.5 ± .5 2.2
Rbx1 NM 014248 Homo sapiens ring-box protein 1 (RBX1) mRNA 1.5 ± .7 2.8 ± .6 2.2
MCM2 D83987 Minichromosome maintenance deficient (S. cerevisiae) 2 
(mitotin)
1.5 ± .3 2.7 ± .3 2.1
MCM4 
(CDC21)
X74794 Minichromosome maintenance deficient (S. cerevisiae) 4 2.0 ± .4 1.8 ± .2 1.9
MCM7 
(cdc47)
D28480 Minichromosome maintenance deficient (S. cerevisiae) 7 1.5 ± .5 2.3 ± .7 1.9BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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(IL-6, IL-11, GP130); b) inflammatory cytokines (LT-b,
LTbR, TNFR1, IL-18, MIF); c) chemokines and their recep-
tors (SDF-1, CXCR4, RANTES, CCR3, SCYC1, SCYE1); d)
members of the PDGF/VEGF growth factor family
(PDGFa, VEGF, VEGF-B, VEGF-C); e) factors belonging to
the TGF-beta family [(TGFb1, bone morphogenetic pro-
teins-1 and -2 (BMP1, BMP2)]; f) anti-inflammatory
cytokines of the IL-10 family (IL-10, IL-19, IL-20). Expo-
sure to Tat of the AV-3 and MCF-7 cell lines was not asso-
ciated with downregulation of any of the tested genes.
Discussion
Our experiments confirm that low concentrations of
extracellular Tat are capable of affecting cell proliferation
and cellular physiology. We have shown that different epi-
thelial cell lines cultured under low-serum conditions are
induced to proliferate by doses of extracellular Tat of at
least 50 ng/ml. The Tat dose used in these experiments
(100 ng/ml) is close to that measured in the plasma of
some HIV-1-infected patients [2–40 ng/ml; [12]]. The
values reported [12] could be underestimated because
local concentrations of Tat in infected tissues are probably
higher as Tat may be sequestered by anti-Tat antibodies
and by glycosaminoglycans. Tat produced in HIV-infected
cells is released extracellularly and is able to stimulate the
growth of Kaposi sarcoma cells at concentrations <1 ng/
ml [34]. In the quoted paper, activation of cells by extra-
cellular Tat required concentrations of 100 ng/ml or
more. Extracellular Tat has also been shown to enhance
the proliferation of germinal center B cells [35] and renal
podocytes [36]. Tat is also involved in the progression of
tumors arising in Tat-transgenic mice [37]. In lymphoid
and neural cells Tat has also been shown to inhibit cell
growth and cause apoptosis [38]. Pathways leading to cell
death depend on the cell lineage and involve activation of
death receptor pathways (i.e., TNF-alpha, Fas, TRAIL),
chemokine receptor signaling, cytokine dysregulation,
caspase activation, calcium mobilization, and loss of
mitochondrial membrane potential.
In HIV replication cycle, Tat is known to interact with the
transcription factor IIF and thereby to increase the activity
of cdk7, thus allowing RNA polymerase II to transcribe the
Tat activation region of the virus LTR [1]. Up-regulation of
cdk7 by exogenous Tat has been demonstrated also in this
study. Using Tat-transfected cell lines [33], Tat was shown
to stimulate mRNA processing through up-regulation of
the cleavage and polyadenylation specificity factor 3
(CPSF3). Up-regulation of CPSF3 was held responsible
for stimulating viral and cellular gene expression. In con-
trast, in our experimental model and within 1 to 12 h
exposure, Tat failed to induce CPSF3 up-regulation. Cell
conditions different from those employed by us may be
operative in Tat-expressing cell lines [33].
Increased expression of several transcription factors and
cyclin/cdk complexes has been observed in Tat-treated
epithelial cells. Genes involved in different phases of the
cell cycle are activated, including genes (e.g., bax) linked
to cell cycle arrest and negative modulation or apoptosis.
These seemingly opposite effects of Tat on cell cycle regu-
lators require some additional comments. Tat may either
act directly on the transcription of negative regulators of
cell cycle, or their up-regulation may be part of a negative
feed back loop generated by an excessive increase of cell
cycle inducers. Within this frame, it is of interest to note
that extracellular Tat can inhibit p53 functions, thus pro-
viding a candidate mechanism through which HIV-1
might contribute to cell cycle dysregulation and
malignant transformation [39]. Indeed, though the
expression of p53 was not increased in epithelial cells
exposed to Tat, the expression of mdm2 (a protein that
binds to p53 and represses the p53-induced transcription
activation) was strongly up-regulated. This is in contrast
to recent findings showing repression of the mdm2 gene
promoter in cells transfected with Tat constructs [33].
p21Cip1 – an important factor whose expression is regu-
lated by p53 and that blocks cell replication in G1 by
inhibiting CDK-cyclin complexes – was strongly up-regu-
lated in Tat-treated cells. Thus, further studies are needed
to assess the balance between activation and inhibition of
cell cycle genes produced by Tat in cells of different line-
ages. These studies might help designing innovative anti-
viral therapies [40]. Measurements of epithelial cell
growth in response to extracellular Tat could represent
auseful model in this context.
As shown in Kaposi sarcoma cells [13,41], our studies
confirm that extracellular Tat up-regulates the expression
of VEGF receptor-2 (Flk-1/KDR). Tat also enhanced the
c-abl X16416 V-abl Abelson murine leukemia viral oncogene homolog 1 1.6 ± .5 1.9 ± .6 1.7
Mdm2 Z12020 Mouse double minute 2, human homolog of p53-binding 
protein
1.6 ± .6 1.8 ± .6 1.7
Rpa L07493 Replication protein A3 (14 Kd) 1.6 ± .5 1.8 ± .4 1.7
1. Mean densitometric values are expressed for each gene as fold difference in cultures exposed to Tat / control cultures not exposed to Tat. 
Negative (pUC18) and positive controls (GAPDH, cyclophillin A, RPL13A, beta-actin) were used to normalize the data. Data are reported only for 
genes that were up-regulated by Tat at least 1.5-fold in both cell lines.
Table 3: Expression profile of cell cycle-related genes in epithelial cell lines exposed for 4 h to exogenous Tat protein (100 ng/ml). BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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expression of multiple angiogenic stimuli (PDGFa, VEGF-
165, VEGF-B, and VEGF-C). This was seen both by RT-
PCR analysis and gene arrays. In addition to stimulating
angiogenesis, these factors are also capable of stimulating
epithelial cell growth by autocrine mechanisms. In renal
mesangial cells, persistent HIV replication was shown to
induce expression of PDGFa/b and TGFb [28], cytokines
that mediate mesangial cell proliferation and extracellular
matrix deposition.
RT-PCR and gene array studies revealed the increased
expression of some chemokine receptors serving as HIV
coreceptors (CXCR4, CCR3, and to a minor extent CCR4).
CXCR4 is the high affinity receptor for SDF-1, while CCR3
binds RANTES. The enhanced expression of CXCR4 and
CCR3 in epithelial cells exposed to Tat suggests that their
susceptibility to T- and M-tropic viruses may be increased
since these cells express basal levels of CD4 and are per-
missive to HIV-1 [29]. Enhanced expression of HIV co-
receptors has also been shown in monocytes [42],
basophils [43], and erythroid cells [44]. Expression of
SDF-1, RANTES and other chemotactic cytokines (SCYC1
and SCYE1) was also increased. The ability of Tat to sign-
althrough chemokines and their receptors is supposed to
attract lymphoid cells toward virus producing cells, thus
favoring the spread ofinfection. Up-regulation of the IL6
family factors (IL6, IL11, GP130) may promote cell
growth [45]. Increased expression of the inflammatory
cytokine LT-b (member of the TNF family) may co-oper-
ate with IL6 in the reactivation of HIV in CD4 T
lymphocytes harboring a latent provirus [46]. Up-regula-
tion of IL18 is also of interest since this cytokine stimu-
lates virus replication. Increased IL18 levels have been
reported in HIV-infected patients [47]. Up-regulation of
MIF expression may contribute to recruit macrophages at
sites of inflammation.
Table 4: Expression profile of cytokine-related genes in epithelial cell lines exposed for 4 h to exogenous Tat protein (100 ng/ml).
Gene name GenBank 
accession No.
Description Fold change in expression1
MCF-7 cell line 
mean ± SD
AV-3 cell line 
mean ± SD
Mean of the 
two cell lines
MIF NM 002415 Macrophage migration inhibitory factor (glycosylation-
inhibiting factor)
5.2 ± .9 2.1 ± 1.8 3.7
IL-19 NM 013371 Interleukin 19 4.0 ± 1.1 2.4 ± .3 3.2
IL-13RA1 NM 001560 Interleukin 13 receptor. alpha 1 4.1 ± 1.2 2.1 ± .6 3.1
GP130 NM 002184 IL-6 signal transducer (gp 130, oncostatin M receptor) 3.9 ± 1.4 2.0 ± .3 3.0
CCR3 NM 001837 Chemokine (CC motif) receptor 3 4.2 ± 1.1 1.6 ± .3 2.9
IL-11 M57765 Interleukin 11 3.9 ± .7 1.7 ± .4 2.8
SCYE1 NM 004757 Small inducible cytokine subfamily E. member 1 (endothelial 
monocyte-activating)
2.6 ± .5 3.0 ± .6 2.8
BMP2 NM 001200 Bone morphogenetic protein 2 3.4 ± .5 2.0 ± .5 2.7
IL-18 NM 001562 Interleukin 18 (interferon-gamma-inducing factor) 2.2 ± .6 3.1 ± .9 2.7
TGFb1 X02812 Transforming growth factor beta 1 (Camurati-Engelmann 
disease)
2.8 ± .5 2.1 ± .4 2.5
SCYC1 U23772 Chemokine (C motif) ligand 1 2.5 ± .6 1.8 ± .4 2.2
BMP1 NM 006128 Bone morphogenetic protein 1 2.7 ± 1.0 1.5 ± .5 2.1
VEGF-C X94216 Vascular endothelial growth factor C 2.5 ± 1.1 1.6 ± .2 2.0
IL-15 AF031167 Interleukin 15 2.0 ± .5 2.0 ± .3 2.0
TNFR1 M33294 Tumor necrosis factor receptor superfamily. member 1A 2.3 ± .7 1.7 ± .5 2.0
VEGF-B U48801 Vascular endothelial growth factor B 2.2 ± .5 1.8 ± .1 2.0
CXCR4 NM 003467 Chemokine (CXC motif) receptor 4 2.1 ± .5 1.5 ± .5 1.8
IL-6 M14584 Interleukin 6 (interferon, beta 2) 2.0 ± .6 1.6 ± .2 1.8
IL-10 M57627 Interleukin 10 (high-level expression in both cell lines) 1.9 ± .5 1.7 ± .4 1.8
LT-b NM 002341 Lymphotoxin beta (TNF superfamily, member 3) 1.8 ± .6 1.6 ± .8 1.7
PDGFa X06374 Platelet-derived growth factor alpha polypeptide 1.7 ± .7 1.7 ± .5 1.7
LTbR L04270 Lymphotoxin beta receptor (TNFR superfamily, member 3) 1.7 ± .2 1.6 ± .4 1.7
SCYA5 / 
RANTES
NM 002985 Chemokine (CC motif) ligand 5 1.6 ± .3 1.7 ± .5 1.6
IL-20 NM 018724 Interleukin 20 1.6 ± .7 1.6 ± .5 1.6
1. Mean densitometric values are expressed for each gene as fold difference in cultures exposed to Tat / control cultures not exposed to Tat. 
Negative (pUC18) and positive controls (GAPDH, cyclophillin A, RPL13A, beta-actin) were used to normalize the data. Data are reported only for 
genes that were up-regulated by Tat at least 1.5-fold in both cell lines.BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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The significance of the increased expression of BMPs is
unclear. BMPs have been identified as factors that induce
ectopic bone and cartilage production. BMPs constitute
the largest subfamily of the TGFb superfamily of growth
factors and exert pleiotropic biological effects ranging
from regulation of early developmental processes to orga-
nogenesis and differentiation of bone, cartilage, epider-
mal and neural tissues [48]. The increased expression of
TGFb found in Tat-treated epithelial cells is a common
feature of HIV-1-infected cells and is thought to be an
important determinant of immunosuppression [49].
Expression of interferon-alpha (a putative immunosup-
pressive factor) could not be detected in epithelial cells
[8].
Expression of the anti-inflammatory cytokines IL-10, IL-
19, and IL-20 appears a remarkable feature of epithelial
cell lines. In particular, high-level expression of IL-10 has
been detected not only in MCF-7 and AV-3 cells, but also
in other mammary and thyroid cell lines. IL-10 is a TH-2
cytokine supposed to limit HIV-1 replication in vivo
through inhibiting the secretion of inflammatory
cytokines (IL-1, TNF-alpha, IL-6, IL-8, IL-12) by lymphoid
cells [10]. IL-10 receptor transcripts (IL-10Ra, IL-10Rb)
have not been detected in Tat-treated epithelial cells. IL-19
and IL-20 are cytokines identified as IL-10 homologs that
share the same receptor complex, indicating that the bio-
logical activities of the two cytokines overlap. Both appear
to regulate development and proper functioning of the
skin. Because the simultaneous presence of both receptor
subunits (IL-20R1 and IL-20R2) is requiredfor IL-19 activ-
ity in a cell, only tissues that express bothsubunits repre-
sent potential targetsfor IL-19. The skin, testis, ovary,
heart, lung, muscle, placenta, adrenal gland, small intes-
tine, and salivary gland appear to express both receptors
[50]. Expression of both IL-19 receptorsubunits in skin is
of a particular interest since IL-19 is up-regulated in psori-
atic skin. As for IL-10, the pattern of expression of IL-19
and IL-20 indicates that these cytokines may be involved
in the regulationof inflammatory responses. Up-regula-
tion of IL-10 has been associated with the mother-to-child
transmission of human cytomegalovirus [51], with peak
replication of feline immunodeficiency virus in vivo [52],
and in HIV-infected patients [53]. Up-regulation of IL-19
mRNA has been observed in Epstein-Barr virus-trans-
formed lymphocytes [54].
Conclusion
Extracellular Tat has a mitogenic effect on mammary and
amniotic epithelial cells and stimulates the expression of
genes of pathogenetic significance in HIV infection. Of
particular interest is that Tat enhances the expression of
anti-inflammatory cytokines of the IL-10 family. These
multiple activities may also help explain the mother-to-
child transmission of HIV.
Methods
Cell cultures
Four lines of mammary epithelial cells have been used:
the spontaneously immortalized MCF-10A cells (non-
tumorigenic), the carcinoma-derived MCF-7 (tumori-
genic, hormone-dependent) cells, the MEC-1 (SV40-
immortalized, non-tumorigenic) and MEC-2 (SV40-
immortalized, tumorigenic, hormone-independent) cells.
MEC-1 and MEC-2 cell lines have been obtained at our
laboratory (32). In addition, the AV-3 line of amniotic ori-
gin was used. Cells were cultured in a 1:1 mixture of
Dulbecco's modified Eagle's medium and F12 medium
(DMEM/F12) supplemented with 10% heat-inactivated
fetal bovine serum (FBS; HyClone Laboratories, Logan,
UT), 4 mM L-glutamine, 1 mM Na-pyruvate, penicillin
and gentamicin. Cell cultures were incubated at 37°C in a
humidified atmosphere containing 5% CO2.
Unless otherwise specified, tissue culture reagents and
chemicals were from Sigma Chemical Co. (St. Louis, MO).
Plasticware was obtained from Falcon (Oxnard, CA).
Molecular biology reagents were from Applied Biosystems
(Monza, Italy).
Tat treatment of cells grown in low-serum-medium (LSM)
Purified recombinant HIV-1 two-exon Tat produced in E.
coli (aa 1-101) was obtained from Intracel (London, UK).
Synthetic Tat (aa 1–86) was chemically synthesized fol-
lowing established procedures (4). Tat was dissolved at 10
µg/ml in DMEM/F12 containing 1 mM dithio-L-threitol.
Tat preparations were shown to be free of endotoxin con-
tamination by the limulus amebocyte lysate assay (BioW-
hittaker Inc., Walkersville, MD). Aliquots were frozen at -
70°C. The two preparations gave equivalent results and
were equally neutralized both by a monoclonal antibody
(1 µg/ml clone tMab-B, IgG1; Intracel) and by rabbit anti-
Tat serum (Intracel).
For studying the effects of Tat on cell growth and gene
expression, cells were plated in complete medium for 24
h and – before Tat treatment – incubated overnight in
LSM to limit the activity of serum growth factors. LSM
consisted of DMEM/F12 containing 0.5% SITE-3 supple-
ment (Sigma), 0.3% dialyzed FBS (10,000 M.W. cut-off),
0.3% human serum albumin, human transferrin (5 µg/
ml), Na-selenite (5 ng/ml). Cell proliferation and gene
expression profiles were compared in control cultures
devoid of Tat and in cultures treated with different con-
centrations of the Tat protein (10–500 ng/ml). For cell
proliferation assays, cultures were exposed to Tat for 1 to
4 days. For analyzing gene expression profiles, cultures
were exposed to Tat for 1 to 12 hr.BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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Cell proliferation assays
A) Cell counts
Five to 7 × 104 epithelial cells were plated for 24 hrs in
wells of 24-well plates (1.9 square cm) with 0.5 ml of
DMEM/F12 containing 10% FCS. Cultures were then
incubated overnight in LSM. The medium was substituted
with LSM containing either no Tat or increasing Tat con-
centrations (10–500 ng/ml). Cultures were examined 24,
48, 72, and 96 h after treatment with an inverted micro-
scope equipped with a 37°C incubation chamber. Images
were acquired with a 10× objective from 6–8 random
fields per culture and recorded with a digital camera. Cell
counts were obtained with a computerized image analysis
system (Image DB; Amplimedical, Mira, Italy) and
expressed as number of cells/well. Each bar represents the
average of three different tests. In Figure 3, standard devi-
ations of the mean are not reported, but were within 12%
of mean values.
In some experiments, the growth-stimulating activity of
Tat was neutralized with a monoclonal antibody to Tat
(clone tMAb-B, 1 µg/ml) or with Tat rabbit antiserum
(1:300 – 1:600 dilution). As a specificity control, a non-
relevant neutralizing mAb to coxsackievirus B4 (clone
356.1, 3 µg/ml) and rabbit neutralizing serum to coxsack-
ievirus B4 (1:300) were used. Control antibodies did not
influence the mitogenic activity of Tat.
B) XTT reduction assay
The assay is based on the ability of viable cells to cleave
the tetrazolium ring of the XTT sodium salt (Sigma) gen-
erating a water-soluble orange compound. Briefly, 1–3 ×
104 epithelial cells per well were cultured for 24 hrs in flat-
bottom 96-well microtiter plates using DMEM/F12 con-
taining 10% FCS. Cultures were then incubated overnight
in LSM to free cells from growth factors present in com-
plete medium. The medium was then substituted with
LSM without phenol red containing either no Tat or
increasing Tat concentrations (10–500 ng/ml). When
stimulated cultures were sub-confluent (1–3 days after
treatment), XTT (200 µg/ml) was added to each well and
cultures were further incubated for 3 hrs. Absorption val-
ues were measured at 450 nm with an ELISA reader. Tests
were done in quadruplicate. As reported for cell count
assays, the Tat neutralizing activity of tMAb-B and Tat rab-
bit antisera was also evaluated by the XTT assay.
Analysis of gene expression by RT-PCR
Semiquantitative RT-PCR was used to evaluate the expres-
sion of selected mRNA transcripts in cell cultures grown
with LSM either in the absence or in the presence of Tat
(100 ng/ml). Cultures in T-25 flasks were treated with Tat
for different times (1, 3, 6, 12 h). Total RNA was extracted
from 3–6 × 106 cells by the guanidinium thiocyanate
method (Life Technologies, Gaithersburg, MD). Experi-
ments were run in duplicate. Total RNA was treated for 1
h at 37°C with DNAse I 2 U/ml in a buffer containing
RNAse inhibitor and MgCl2 2 mM. DNAse I was inacti-
vated for 5 min at 90°C. cDNA was obtained from 2 µg of
RNA with Mo-MLV reverse transcriptase in conjunction
with random hexamer primers (Clontech, Palo Alto, CA).
Cytokine-specific primer pairs obtained by Clontech
(Cytokine MAPPing Amplimers) were used to amplify a
variety of cytokines. Reagents from Maxim Biotech (San
Francisco, CA) were used to detect transcripts of vascular
endothelial growth factor (VEGF 121, 165, and 189
isoforms) and the VEGF receptor-2 (Flk/KDR). A series of
published primers specific to HIV receptors, growth-fac-
tors, and a factor involved in pre-mRNA maturation were
used (Table 1). Expression of the following transcripts was
analyzed: IL-6, IL-6-R, IL-8, TGF-beta1, TGF-beta2, CD4,
CXCR4, CCR1, CCR2, CCR3, CCR4, CCR5, CPSF3 (cleav-
age and polyadenylation specificity factor-3). The Applied
Biosystems model 2400 thermal cycler was used for PCR
reactions using AmpliTaq Gold polymerase (2 units) in a
final volume of 50 µl. Samples were denatured at 94°C for
10 minutes before cycling for 21–25 cycles. Amplicons
were analyzed on 2% agarose gel using ethidium bromide
staining and were photographed on a transilluminator
(Kodak Image Station440). Amplicons were quantified
using the Kodak 1D 3.5 software using beta-actin and
GAPDH transcripts to normalize the data. For selected
genes (IL-6, IL-6-R, TGF-beta1, VEGF isoform 165), the
relative gene expression obtained by microarray technol-
ogy was confirmed using real-time PCR. A real-time PCR
instrument (Smart Cycler; Cepheid, Sunnyvale, CA) was
used together with SYBR Green PCR Master Mix and
AmpliTaq Gold DNA polymerase obtained from Applied
Biosystems. Reactions were carried out in a final volume
of 25 µl. No-amplification control tubes containing sam-
ples, but no enzyme were included in each run to exclude
the presence of fluorescent contaminants. Conditions
consisted of an initial 10-min hold at 95°C followed by
40 amplification cycles. Real-time data were collected dur-
ing the extension step of each cycle. Amplification of
human beta-actin was used as a positive control and for
normalizing data. Upon normalization with Ct values of
beta-actin amplification, threshold cycle numbers (Ct)
obtained for Tat-treated cultures were compared to those
obtained for untreated control cultures.
Analysis of gene expression by gene arrays
GE Array™ Q series membranes (HS-001, HS-003, and
HS-015 non-radioactive kits; Superarray, Bethesda, MD)
were used to characterize gene expression profiles associ-
ated with Tat treatment. Membranes contained 96 cDNA
tetraspots of human genes associated with specific biolog-
ical pathways (cell cycle, common cytokines, inflamma-
tory cytokines and receptors). pUC18 DNA was used as a
negative control, and housekeeping genes (beta-actin,BMC Microbiology 2005, 5:20 http://www.biomedcentral.com/1471-2180/5/20
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cyclophillin A, ribosomal protein L13a, GAPDH) as posi-
tive controls. To evaluate the pattern of induced or sup-
pressed gene expression in response to Tat treatment, side-
by-side hybridizations with samples from untreated and
Tat-treated cultures were performed. Total RNA was
extracted from confluent cell monolayers grown with LSM
in T-25 flasks and treated or not with Tat. Preliminary
experiments with Tat treatment given from 1 to 12 hr,
indicated that 4 h was the optimal treatment time. Bioti-
nylated probe synthesis was performed using mixtures of
primers proper to each gene set. Before probe synthesis,
RNA samples were analyzed and quantified by agarose gel
electrophoresis. RNA samples (1–5 µg) combined with
the primer mix were added with a prewarmed labeling
mix containing 50 units of Mo-MLV reverse transcriptase,
20 units of RNase inhibitor and a dNTP mix containing 2
nmol of biotin-16-dUTP (Roche Applied Science, Monza,
Italy) and incubated at 42°C for 90 min. GE Array mem-
branes were prehybridized for 1 h with GEAhyb buffer
containing 100 µg/ml heat-denatured salmon sperm DNA
(Life Technologies) to prevent non-specific hybridization.
Membranes were hybridized overnight at 60°C with
denatured cDNA probes using the kit hybridization buffer
and hybridization bottles rotating at 10 rpm. After exten-
sive washing (60°C) at low and high stringency condi-
tions in rotating hybridization bottles (10 rpm),
membranes were incubated for 10 min with alkaline
phosphatase-conjugated streptavidin (AP-streptavidin
1:7.500). Gene expression was detected by chemilumines-
cence using the AP substrate CDP-Star. Chemilumines-
cence signals were recorded on X-OMAT film (Kodak,
Rochester, NY) using exposure times of 0.5 to 8 minutes.
After development, X-OMAT films were scanned with a
high-definition scanner (Coolscan 4000 ED, Nikon,
Tokyo, Japan). Dedicated software (Gene-Analyzer,
Superarray Inc.) was used for densitometric analysis.
Experiments on MCF-7 and AV-3 cells were repeatedthree
times.
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